Tucatinib
Brand: Tukysa (global)
Anticancer
HER2 selective TKI
Pharmacokinetics
| Half-life | 13 hours |
| Tmax | 2 h |
| Protein Binding | 99 % |
| Volume of Distribution | 903 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Selective for HER2 → lower EGFR-mediated diarrhoea vs lapatinib/neratinib; good CNS penetration. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Hepatotoxicity, diarrhoea, stomatitis, fatigue
Contraindications:
Severe hepatic failure
Precautions:
Monitor LFTs frequently especially first 2 months; adjust dose with hepatotoxicity